Business Wire: September 14, 2017 – NEW YORK, NY, and SAN DIEGO, CA, U.S.A. – Bristol-Myers Squibb Company (NYSE: BMY) and Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement to develop subcutaneously administered Bristol-Myers Squibb immuno-…
